Table 4.
Distribution of treatments received and progression of dieses between both groups
| Treatment | C3GN (n = 10) |
C3 Controls (n = 21) |
p value |
|---|---|---|---|
| aRAS blockers (%) | 70 (n = 7) | 85 (n = 18) | 0.3 |
| Steroids (%) | 30 (n = 3) | 72 (n = 15) | 0.05 |
| bMMF (%) | 20 (n = 2) | 33 (n = 7) | 0.4 |
| cTac (%) | 0 | 10 (n = 2) | 1 |
| dCP (%) | 10 (n = 1) | 14 (n = 3) | 1 |
| eCsA (%) | 0 | 19 (n = 4) | 0.3 |
| fAZA (%) | 0 | 10 (n = 2) | 1 |
| No immunosuppression (%) | 40 (n = 4) | 28 (n = 6) | 0.7 |
| Missing data (%) | 20 (n = 2) | 0 | 0.09 |
| Immunosuppression (%) | 40 (n = 4) | 72 (n = 15) | 0.4 |
| Median Duration of immunosuppression (days) | 263 (IQR 126–629) | 302 (IQR 184–1496) | 0.5 |
Mann Whitney and Fishers exact test used
aRAS Renin-angiotensin system blockade, bMMF Mycophenolate mofetil, cTac Tacrolimus, dCP cyclophosphamide, eCsA Ciclosporin, fAZA azathioprine